Clinical Trial

Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 17, 2021 (before its estimated February 28, 2024 completion). Its status may not reflect the trial's current state.
Summary
This trial will assess the feasibility of alpha/beta T-cell and B-cell depleted allogeneic hematopoietic cell transplantation (HCT) followed by blinatumomab therapy for high-risk B cell acute lymphoblastic leukemia (ALL) as a means of reducing rates of subsequent relapse and improving survival, while also minimizing treatment-related morbidity/ mortality and late effects. The conditioning regimens will be dependent on the patient's minimal residual disease (MRD) status prior to HCT using high throughput sequencing.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-02-08; most recent amendment 2025-08-06.
Status change: Recruiting → Terminated 2025-05-12
Status change: Not Yet Recruiting → Recruiting 2021-06-22
Trial Details
NCT Number NCT04746209
Lead Sponsor Medical College of Wisconsin
Collaborators: Amgen, University of Wisconsin, Madison
Conditions B-cell Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-Cell ALL, Childhood
Enrollment 25 participants
Start Date 2021-02-01
Primary Completion 2024-02-28 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2021-09-17